Amplia Therapeutics (ASX:ATX) is a clinical-stage biotechnology company developing narmafotinib, a FAK inhibitor, in combination with chemotherapy for pancreatic cancer — one of the deadliest and most treatment-resistant cancers, with a high unmet medical need. A therapy that meaningfully improves outcomes in pancreatic cancer would be highly significant, which is why encouraging trial data attracts strong attention.

Amplia reported that its ACCENT trial of narmafotinib plus chemotherapy in pancreatic cancer produced multiple complete responses — cases where tumours were no longer detectable — along with improved overall survival data, and it presented ACCENT results at the 2026 ASCO Gastrointestinal Cancer Symposium. The company highlighted additional complete responses as sharpening the case for narmafotinib.

What Could Drive the Shares Next?

Catalysts include further ACCENT data — particularly the durability of responses and survival benefit — the design and initiation of larger trials, regulatory interactions, and any partnering interest. Confirmation of the efficacy signal in a larger study would be transformative given the unmet need.

Continued positive data and a clear path to a pivotal trial would be the clearest drivers.

Risks Investors Should Watch

Pancreatic-cancer Drug Development is notoriously difficult, and early complete responses may not translate into a confirmed benefit in larger trials. Amplia is dependent on capital markets, and further raisings are likely.

Clinical risk is binary, value is concentrated in a single program, and the competitive oncology landscape adds uncertainty.

Investor Takeaway

Amplia Therapeutics has reported striking complete responses and improved survival data for narmafotinib in pancreatic cancer through its ACCENT trial. Whether the market is underestimating the story depends on confirming those signals in larger studies. ACCENT data, the path to a pivotal trial and the cash position are the things to watch.